Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in share interests for Roger Connor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific insider trading disclosures and does not contain consolidated financial statements.
Material Changes
The filing details the following transactions executed by Roger Connor, a Person Discharging Managerial Responsibility, on March 22, 2016:
- Exercise of a nil cost option over 3,680 Ordinary Shares granted on February 28, 2013, and vested on February 28, 2016.
- Sale of 3,680 Ordinary Shares at a price of £13.78 per share.
- Sale of 19,320 Ordinary Shares at a price of £13.76 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of share transactions.
Investor Verification Points
- Verify the total number of shares sold by Roger Connor (23,000 shares) against his total holdings to assess net position changes.
- Confirm the share price range (£13.76–£13.78) against the market price on March 22, 2016.
- Review the vesting schedule of the Deferred Annual Bonus Plan to understand the timing of the option grant and exercise.